Your browser doesn't support javascript.
loading
Direct health care cost of treatment and medication of biliary atresia patients using the National Database of Health Insurance Claims and Specific Health Checkups.
Hoshino, Eri; Konomura, Keiko; Obatake, Masayuki; Moriwaki, Kensuke; Sakai, Michi; Urayama, Kevin Y; Shimozuma, Kojiro.
Afiliación
  • Hoshino E; Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Ritsumeikan University, Kyoto, Japan. hoshieri@fc.ritsumei.ac.jp.
  • Konomura K; Graduate School of Public Health, St. Luke's International University, Tokyo, Japan. hoshieri@fc.ritsumei.ac.jp.
  • Obatake M; Center for Outcomes Research and Economic Evaluation for Health (C2H), National Institute of Public Health, Saitama, Japan.
  • Moriwaki K; Department of Pediatric Surgery, Kochi Medical School, Nankoku, Japan.
  • Sakai M; Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Ritsumeikan University, Kyoto, Japan.
  • Urayama KY; Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Ritsumeikan University, Kyoto, Japan.
  • Shimozuma K; Graduate School of Public Health, St. Luke's International University, Tokyo, Japan.
Pediatr Surg Int ; 38(4): 547-554, 2022 Apr.
Article en En | MEDLINE | ID: mdl-35165784
ABSTRACT

BACKGROUND:

Treatment of biliary atresia (BA), which typically requires an initial surgical intervention called the Kasai procedure (KP) and possible liver transplant (LT) afterwards, is quite resource-intensive and would affect patients and families for a lifetime; yet a comprehensive view of the economic burden has not been reported. We estimated direct health care costs from the public payer perspective using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.

METHODS:

Children newly diagnosed at ages 0 days to 4 years between April 2010 and September 2019 were identified. Costs of treatment were estimated for six phases of care prediagnosis, KP and inpatient hospitalization, follow-up after KP, pre-transplant checkup, LT and inpatient hospitalization, and follow-up after LT.

RESULTS:

Mean total prediagnosis medical cost was $6847 (USD) and KP and inpatient hospitalization was $42,157 per year. Follow-up after KP was $15,499, and pre-transplant checkup after KP was $36,015 per year. Mean cost for LT and inpatient hospitalization was $105,334, and follow-up after liver transplant was $25,459 per year.

CONCLUSIONS:

Treatment of BA requires extensive medical resource consumption. The use of the comprehensive national database allowed us to estimate the costs which will be useful for health service planning and cost-effectiveness analysis.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Atresia Biliar / Trasplante de Hígado Tipo de estudio: Diagnostic_studies / Health_economic_evaluation / Observational_studies / Prognostic_studies Límite: Child / Humans / Newborn Idioma: En Revista: Pediatr Surg Int Asunto de la revista: PEDIATRIA Año: 2022 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Atresia Biliar / Trasplante de Hígado Tipo de estudio: Diagnostic_studies / Health_economic_evaluation / Observational_studies / Prognostic_studies Límite: Child / Humans / Newborn Idioma: En Revista: Pediatr Surg Int Asunto de la revista: PEDIATRIA Año: 2022 Tipo del documento: Article País de afiliación: Japón